Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement

Australasian Journal of Dermatology

Volumn 56, Issue 4, 2015, Pages 241-251

  Mooney, Emma ^a   Rademaker, Marius ^b   Dailey, Rebecca ^c   Daniel, Ben S ^a   Drummond, Catherine ^d,p   Fischer, Gayle ^e,l   Foster, Rachael ^f   Grills, Claire ^a   Halbert, Anne ^f   Hill, Sarah ^b   King, Emma ^a   Leins, Elizabeth ^a   Morgan, Vanessa ^a,g   Phillips, Roderic J ^a,h,n   Relic, John ⁱ   Rodrigues, Michelle ^a,j   Scardamaglia, Laura ^a,c,g,k   Smith, Saxon ^e,l   Su, John ^a,c,h,m,n   Wargon, Orli ^o   Orchard, David ^a   more..

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b WAIKATO HOSPITAL   (New Zealand)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CANBERRA HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h MONASH UNIVERSITY   (Australia)

ⁱ Royal Newcastle Centre   (Australia)

^j ST VINCENT S HOSPITAL   (Australia)

^k WESTERN HOSPITAL   (Australia)

^l UNIVERSITY OF SYDNEY   (Australia)

^m EASTERN HEALTH   (Australia)

ⁿ MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^o SYDNEY CHILDREN'S HOSPITAL   (Australia)

^p AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CORTICOSTEROID; DERMATOLOGICAL AGENT;

ADRENAL SUPPRESSION; ATOPIC DERMATITIS; ATROPHY; AUSTRALIAN; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; DERMATITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; ECZEMA; EYE DISEASE; HOT FLUSH; HUMAN; HYPERTRICHOSIS; HYPOPIGMENTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; OSTEOPENIA; OSTEOPOROSIS; PERIORIFICIAL DERMATITIS; PRACTICE GUIDELINE; PURPURA; QUALITY OF LIFE; REVIEW; ROSACEA; RUBRA DISTENSAE; SKIN ALLERGY; SKIN ATROPHY; SKIN DISEASE; SKIN INFECTION; STRIA; TACHYPHYLAXIS; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT; AUSTRALIA; CHEMICALLY INDUCED; CHILD; CONSENSUS; CUTANEOUS DRUG ADMINISTRATION; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLIC BONE DISEASE; PATHOLOGY; PRESCHOOL CHILD; SKIN;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ATROPHY; AUSTRALIA; BONE DISEASES, METABOLIC; CHILD; CHILD, PRESCHOOL; CONSENSUS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; EYE DISEASES; HUMANS; HYPERTRICHOSIS; HYPOPIGMENTATION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; OSTEOPOROSIS; PITUITARY-ADRENAL SYSTEM; PURPURA; ROSACEA; SKIN; STRIAE DISTENSAE; TACHYPHYLAXIS; TELANGIECTASIS;

EID: 84956665352     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12313     Document Type: Review

References (105)

1. Kay J, Gawkrodger DJ, Mortimer MJ, et al. The prevalence of childhood atopic eczema in a general population. J. Am. Acad. Dermatol. 1994; 30: 35-39.
2. Robertson CF, Dalton MF, Peat JK, et al. Asthma and other atopic diseases in Australian children. Australian arm of the International Study of Asthma and Allergy in Childhood. Med. J. Aust. 1998; 168: 434-438.
3. Martin PE,. The epidemiology of infantile eczema (thesis). Royal Children's Hospital: University of Melbourne; 2011.
4. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch. Dis. Child. 1997; 76: 159-162.
5. Lewis-Jones S,. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int. J. Clin. Pract. 2006; 60: 984-992.
6. Sulzberger MB, Witten VH,. The effect of topically applied compound F in selected dermatoses. J. Invest. Dermatol. 1952; 19: 101-102.
7. Warner MR, Camisa C,. Topical corticosteroids. In:, Wolverton SE, (ed.). Comprehensive Dermatologic Drug Therapy, 3rd edn. Philadelphia (PA): Elsevier Health Sciences, 2013; 487-505.
8. Maibach HI,. In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatology 1976; 152: 11-25.
9. Barry BW,. Bioavailability of topical steroids. Dermatologica. 1976; 152 (Suppl 1): 47-65.
10. Gao HY, Li Wan Po A,. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity? Eur. J. Clin. Pharmacol. 1994; 46: 71-75.
11. Wester RC, Maibach HI,. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab. Rev. 1983; 14: 169-205.
12. Stoughton RB,. Vasoconstrictor activity and percutaneous absorption of glucocorticosteroids: a direct comparison. Arch. Dermatol. 1969; 99: 753-756.
13. Gibson JRJ,. Correlation of the vasoconstrictor assay and clinical activity in psoriasis. Arch. Dermatol. 1985; 121: 1105-5.
14. Barry BW, Woodfordf R,. Activity and bioavailability of topical steroids. In vivo/in vitro correlations for the vasoconstrictor test. J. Clin. Pharm. Ther. 1978; 3: 43-65.
15. Marks R, Barlow JW, Funder JW,. Steroid-induced vasoconstriction: glucocorticoid antagonist studies. J. Clin. Endocrinol. Metab. 1982; 54: 1075-1077.
16. Smith SDS, Hong EE, Fearns SS, et al. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas. J. Dermatol. 2010; 51: 168-174.
17. Long CCC, Mills CMC, Finlay AYA,. A practical guide to topical therapy in children. Br. J. Dermatol. 1998; 138: 293-296.
18. Long CC, Finlay AY,. The finger-tip unit-a new practical measure. Clin. Exp. Dermatol. 1991; 16: 444-447.
19. Eaglstein WH, Mertz PM,. New method for assessing epidermal wound healing: the effects of triamcinolone acetonide and polyethelene film occlusion. J. Invest. Dermatol. 1978; 71: 382-384.
20. Chernosky ME, Knox JM,. Atrophic striae after occlusive corticosteroid therapy. Arch. Dermatol. 1964; 90: 15-19.
21. Epstein NN, Epstein WL, Epstein JH,. Atrophic striae in patients with inguinal intertrigo: pathogenesis. Arch. Dermatol. 1963; 87: 450-457.
22. Lehmann P, Zheng P, Lavker RM, et al. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J. Invest. Dermatol. 1983; 81: 169-176.
23. Burrows NP, Lovell CR,. Disorders of connective tissue. In:, Burns T, Breathnach S, Cox N, et al. (eds). Rook's Textbook of Dermatology, 8th edn. Oxford: John Wiley, 2010; Ch 45.2-454.
24. Sheu HM, Chang CH,. Alterations in water content of the stratum corneum following long-term topical corticosteroids. J. Formos. Med. Assoc. 1991; 90: 664-669.
25. Delforno C, Holt PJ, Marks R,. Corticosteroid effect on epidermal cell size. Br. J. Dermatol. 1978; 98: 619-623.
26. Lubach D, Grüter H, Behl M, et al. Investigations on the development and regression of corticosteroid-induced thinning of the skin in various parts of the human body during and after topical application of amcinonide. Dermatologica. 1988; 178: 93-97.
27. Hong E, Smith S, Fischer G,. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr. Dermatol. 2011; 28: 393-396.
28. Frosch PJ, Behrenbeck EM, Frosch K, et al. The Duhring chamber assay for corticosteroid atrophy. Br. J. Dermatol. 1980; 104: 57-65.
29. Vázquez-Lõpez F, Kreusch J, Marghoob AA,. Dermoscopic semiology: further insights into vascular features by screening a large spectrum of nontumoral skin lesions. Br. J. Dermatol. 2004; 150: 226-231.
30. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br. J. Dermatol. 2001; 140: 1115-1121.
31. Thomas KS,. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002; 324: 768-8.
32. Burrows NP, Lovel CR,. Disorders of connective tissue. In:, Burns T, Breathnach S, Cox N, et al. (eds). Rook's Textbook of Dermatology, 8th edn. Oxford: John Wiley, 2010; Ch 45.5.
33. Aschoff R, Schmitt J, Knuschke P, et al. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp. Dermatol. 2011; 20: 832-836.
34. Ammar NM, Rao B, Schwartz RA, et al. Adolescent striae. Cutis 2000; 65: 69-70.
35. Levin E, Gupta R, Butler D, et al. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression. J. Dermatolog. Treat. 2014; 25: 501-506.
36. Irving Katz H, Hien NT, Prawer S, et al. Superpotent topical steroid treatment of psoriasis vulgaris-clinical efficacy and adrenal function. J. Am. Acad. Dermatol. 1987; 16: 804-811.
37. Eriksen K,. Comparison of clobetasol propionate and betamethasone-17,21-dipropionate with reference to adrenal suppression. Acta Derm. Venereol. 1978; 59: 372-374.
38. Munro DD,. Topical corticosteroid therapy and its effect on the hypothalamic-pituitary-adrenal axis. Dermatology 1976; 152: 173-180.
39. Tempark TT, Phatarakijnirund VV, Chatproedprai SS, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine 2010; 38: 328-334.
40. Curtis JA, Cormode E, Laski B, et al. Endocrine complications of topical and intralesional corticosteroid therapy. Arch. Dis. Child. 1982; 57: 204-207.
41. Ermis B, Ors R, Tastekin A, et al. Cushing's syndrome secondary to topical corticosteroids abuse. Clin. Endocrinol. (Oxf) 2003; 58: 795-796.
42. Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J. Pediatr. Endocrinol. Metab. 2007; 20: 219-225.
43. Ruiz-Maldonado R,. Cushing's syndrome after topical application of corticosteroids. Arch. Pediatr. Adolesc. Med. 1982; 136: 274.
44. Al-Khenaizan S, Alwan AI,. Topical steroid-induced Cushing syndrome. Ann. Saudi Med. 2008; 28: 300-302.
45. Saeki H, Watanabe A, Tada Y, et al. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid. J. Dermatol. 2008; 35: 601-603.
46. Atabek ME, Pirgon O, Unal E,. Pituitary-adrenal axis suppression due to topical steroid administration in an infant. Pediatr. Int. 2007; 49: 242-244.
47. Siklar Z, Bostanci I, Atli O, et al. An infantile Cushing syndrome due to misuse of topical steroid. Pediatr. Dermatol. 2004; 21: 561-563.
48. Guven A, Karadeniz S, Aydin O, et al. Fatal disseminated cytomegalovirus infection in an infant with Cushing's syndrome caused by topical steroid. Horm. Res. 2004; 64: 35-38.
49. Semiz S, Balci YI, Ergin S, et al. Two cases of Cushing's syndrome due to overuse of topical steroid in the diaper area. Pediatr. Dermatol. 2008; 25: 544-547.
50. Hill SE, Yung A, Rademaker M,. Prevalence of Staphylococcus aureus and antibiotic resistance in children with atopic dermatitis: a New Zealand experience. Australas. J. Dermatol. 2011; 52: 27-31.
51. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br. J. Dermatol. 2006; 155: 680-687.
52. Netchiporouk E, Cohen BA,. Recognizing and managing eczematous id reactions to Molluscum contagiosum virus in children. Pediatrics 2012; 129: e1072-1075.
53. Treadwell PA,. Eczema and infection. Pediatr. Infect. Dis. J. 2008; 27: 551-552.
54. Nilsson EJ, Henning CG, Magnusson J,. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J. Am. Acad. Dermatol. 1992; 27: 29-34.
55. Wilkinson SM, English JS,. Hydrocortisone sensitivity: clinical features of fifty-nine cases. J. Am. Acad. Dermatol. 1992; 27 (5 Pt 1): 683-687.
56. Venturini M, Lobera T, Del Pozo MD, et al. Immediate hypersensitivity to corticosteroids. J. Investig. Allergol. Clin. Immunol. 2006; 16: 51-56.
57. Wilkinson SM, Jones MF,. Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Br. J. Dermatol. 1996; 135: 225-230.
58. Wilkinson DS, Wilkinson JD,. Comparison of patch test results in two adjacent areas of England I. (Industrial allergens). Acta Derm. Venereol. Suppl. 1978; 59: 189-192.
59. Thomson KFK, Wilkinson SMS, Powell SS, et al. The prevalence of corticosteroid allergy in two U.K. centres: prescribing implications. Br. J. Dermatol. 1999; 141: 863-866.
60. Dooms-Goossens A, Meinardi MM, Bos JD, et al. Contact allergy to corticosteroids: the results of a two-centre study. Br. J. Dermatol. 1993; 130: 42-47.
61. Goossens D, Andersen KE, Brandäo FM, et al. Corticosteroid contact allergy: an EECDRG multicentre study. Contact Dermatitis. 1996; 35: 40-44.
62. Foti C, Bonifazi E, Casulli C, et al. Contact allergy to topical corticosteroids in children with atopic dermatitis. Contact Dermatitis. 2005; 52: 162-163.
63. Browne F, Wilkinson SM,. Effective prescribing in steroid allergy: controversies and cross-reactions. Clin. Dermatol. 2010; 29: 287-294.
64. Picado C, Luengo M,. Corticosteroid-induced bone loss. Prevention and management. Drug Saf. 1996; 15: 347-359.
65. Adinoff AD, Hollister JR,. Steroid-induced fractures and bone loss in patients with asthma. N. Engl. J. Med. 1983; 309: 265-268.
66. van Staa TPT, Cooper CC, Leufkens HGMH, et al. Children and the risk of fractures caused by oral corticosteroids. J. Bone Miner. Res. 2003; 18: 913-918.
67. Pedreira CC, King E, Jones G, et al. Oral cyclosporin plus topical corticosteroid therapy diminishes bone mass in children with eczema. Pediatr. Dermatol. 2007; 24: 613-620.
68. Cueto-Manzano AM, Konel S, Crowley V, et al. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 2003; 75: 2053-2058.
69. Thiébaud D, Krieg MA, Gillard-Berguer D, et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur. J. Clin. Invest. 1996; 26: 549-555.
70. van Velsen SGAS, Knol MJM, van Eijk RLAR, et al. Bone mineral density in children with moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2010; 63: 8-8.
71. Becker B,. The effect of topical corticosteroids in secondary glaucomas. Arch. Ophthalmol. 1964; 72: 769-771.
72. Haeck IM, Rouwen TJ, Mik LT-D, et al. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J. Am. Acad. Dermatol. 2011; 64: 275-281.
73. Aggarwal RK, Potamitis T, Chong NH, et al. Extensive visual loss with topical facial steroids. Eye (Lond) 1992; 7 (Pt 5): 664-666.
74. Cubey RB,. Glaucoma following the application of corticosteroid to the skin of the eyelids. Br. J. Dermatol. 1976; 95: 207-208.
75. Eisenlohr JE,. Glaucoma following the prolonged use of topical steroid medication to the eyelids. J. Am. Acad. Dermatol. 1983; 8: 878-881.
76. David DS, Berkowitz JS,. Ocular effects of topical and systemic corticosteroids. Lancet 1969; 2: 149-151.
77. Branco N, Branco BC, Maibach HI,. Cutaneous corticosteroid therapy and cataract in man. Cutan. Ocul. Toxicol. 2002; 21: 161-168.
78. Berth-Jones J,. Rosacea, perioral dermatitis and similar dermatoses, flushing and flushing syndromes. In:, Burns T, Breathnach S, Cox N, et al. (eds). Rook's Textbook of Dermatology, 8th edn. Oxford: John Wiley, 2010; Ch 43.11.
79. Nguyen V, Eichenfield LF,. Periorificial dermatitis in children and adolescents. J. Am. Acad. Dermatol. 2006; 55: 781-785.
80. Teraki Y, Hitomi K, Sato Y, et al. Tacrolimus-induced rosacea-like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology 2011; 224: 309-314.
81. Fujiwara SS, Okubo YY, Irisawa RR, et al. Rosaceiform dermatitis associated with topical tacrolimus treatment. J. Am. Acad. Dermatol. 2010; 62: 1050-1052.
82. Bernard LA, Cunningham BB, Al-Suwaidan S, et al. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch. Dermatol. 2003; 139: 229-231.
83. Hafeez ZH,. Perioral dermatitis: an update. Int. J. Dermatol. 2003; 42: 514-517.
84. Rapaport MJ, Rapaport V,. The red skin syndromes: corticosteroid addiction and withdrawal. Expert Rev Dermatol. 2006; 1: 547-561.
85. du Vivier A,. Tachyphylaxis to topically applied steroids. Arch. Dermatol. 1976; 112: 1245-1248.
86. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367-7.
87. Miller JJ, Roling D, Margolis D, et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J. Am. Acad. Dermatol. 1999; 41: 546-549.
88. Taheri A, Cantrell J, Feldman SR,. Tachyphylaxis to topical glucocorticoids; what is the evidence? Dermatol. Online J. 2013; 19: 18954.
89. Singh G, Singh PK,. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int. J. Dermatol. 1986; 25: 324-327.
90. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J. Am. Acad. Dermatol. 2007; 56: 211-216.
91. Charman CR, Morris AD, Williams HC,. Topical corticosteroid phobia in patients with atopic eczema. Br. J. Dermatol. 2000; 142: 931-936.
92. Feinstein RJ, Halprin KM, Penneys NS, et al. H. Senile purpura. QJM 1961; 30: 33-40.
93. Shuster S, Scarborough H,. Senile Purpura. QJM 1961; 30: 33-40.
94. Chernosky ME,. Adverse side-effects after topical fluorinated corticosteroid therapy. Arch. Dermatol. 1973; 108: 132.
95. Olsen EA,. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch. Dermatol. 1991; 127: 197-201.
96. Friedman SJ, Butler DF, Pittelkow MR,. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. J. Am. Acad. Dermatol. 1988; 19: 537-541.
97. Kestel JL,. Hypopigmentation following the use of Cordran tape. Arch. Dermatol. 1971; 103: 460.
98. Vachiramon V, Thadanipon K,. Postinflammatory hypopigmentation. Clin. Exp. Dermatol. 2011; 36: 708-714.
99. Berth-Jones J,. Eczema, lichenification, prurigo & erythema. In:, Burns T, Breathnach S, Cox N, et al. (eds). Rook's Textbook of Dermatology, 8th edn. Oxford: John Wiley, 2010; 27-30.
100. Smith JG, Wehr RF, Chalker DK,. Corticosteroid-induced cutaneous atrophy and telangiectasia. Experimental production associated with weight loss in rats. Arch. Dermatol. 1976; 112: 1115-1117.
101. Serup J, Holm P,. Domoprednate (stermonid), a topical d-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. Dermatologica 1985; 170: 189-194.
102. Kuokkanen K, Sillantaka I,. Alclometasone dipropionate 0.05% vs hydrocortisone 1.0%: potential to induce cutaneous atrophy in children. Clin. Ther. 1986; 9: 223-231.
103. Tirlapur VG, Rice-Oxley JM,. Facial erythema and telangiectasia with synalar cream. Br. J. Clin. Pract. 1981; 35: 275-276.
104. Hogan DJ, Rooney ME,. Facial telangiectasia associated with long-term application of a topical corticosteroid to the scalp. J. Am. Acad. Dermatol. 1989; 20: 1129-1130.
105. Stevanovic DV,. Corticosteroid-induced atrophy of the skin with telangiectasia. A clinical and experimental study. Br. J. Dermatol. 1972; 87: 548-556.